GORD forsaken XenoPort seeks redemption in spasticity for arbaclofen
This article was originally published in Scrip
Executive Summary
XenoPort has halted development of its investigational candidate arbaclofen placarbil as a treatment for gastro-oesophageal reflux disease (GORD) after the drug, at four doses, failed to meet the main goal in a Phase IIb trial. But the company still hopes that ongoing trials of the drug in treating spasticity will redeem its clinical future.